eptin acts centrally to increase sympathetic nerve activity (SNA) to several organs (for review, see Harlan and Rahmouni 1 ), including the kidneys (renal SNA), the hindquarters (lumbar SNA; LSNA), brown adipose tissue, and the splanchnic circulation.
L
eptin acts centrally to increase sympathetic nerve activity (SNA) to several organs (for review, see Harlan and Rahmouni 1 ), including the kidneys (renal SNA), the hindquarters (lumbar SNA; LSNA), brown adipose tissue, and the splanchnic circulation. [2] [3] [4] Multiple hypothalamic nuclei have been identified as sites that initiate the increases in SNA: the ventral medial hypothalamus, arcuate nucleus (ArcN), dorsal medial hypothalamus, and lateral hypothalamus. [5] [6] [7] [8] [9] [10] Leptin has also been shown to increase arterial pressure when administered into the paraventricular nucleus (PVN) of the hypothalamus, 8, 11 but increases in SNA have not been observed. 5, 8 More recently, the subfornical organ was shown to be required for the action of leptin in plasma to increase renal SNA, but not brown adipose tissue SNA. 12 Although leptin acts in many brain sites to initiate its sympathoexcitatory effects, only limited information is available regarding the neurocircuitry that mediates increased SNA after leptin receptor binding. All hypothalamic sites that respond to leptin send projections to the PVN. [13] [14] [15] Therefore, the first purpose of the present study was to test whether these pathways converge in the PVN by determining if local inhibition of the PVN, via bilateral nanoinjection of the gamma aminobutyric acid type A agonist, muscimol, completely reverses the effects of leptin to increase LSNA. We infused leptin intracerebroventricularly so that multiple nuclei could be targeted; we measured LSNA because this sympathetic nerve has been shown to be activated by leptin in many hypothalamic sites 8 ; and we measured baroreflex function so that the effects of leptin could be assessed over a range of arterial pressure levels.
Two potential excitatory inputs to the PVN that may mediate the sympathoexcitatory effects of leptin are α-melanocytestimulating hormone (α-MSH) and glutamate. Indeed, intracerebroventricular (ICV) administration of α-MSH or the MC3/4R agonist melanotan II (MTII) increased SNA, [16] [17] [18] [19] whereas broad brain inhibition of MC3/4R with ICV SHU9119 or Agouti-related protein blocked the sympathoexcitatory effects of leptin. 16, 17 α-MSH is derived and released from proopiomelanocortin neurons, which are situated in the ArcN and project to several hypothalamic sites involved in autonomic regulation, including the PVN, 14, 20, 21 but the specific role of PVN MC3/4 is unclear. In parallel, the PVN receives glutamatergic inputs from many sites at which leptin increases SNA, including the ventral medial hypothalamus, dorsal medial hypothalamus, ArcN, and lateral hypothalamus. 15 Moreover, a subset of ArcN pro-opiomelanocortin neurons coexpress the glutamate vesicular transporter (VGLUT-2), 22 and blockade of PVN glutamate receptors reduces the sympathoexcitatory effects of nonspecific chemical stimulation of the ArcN. 23 In addition to excitatory inputs, inhibitory ArcN neuropeptide Y (NPY) neurons project to the PVN. 24, 25 ArcN leptin inhibits NPY neurons, 26, 27 and NPY inhibits the firing of PVN neurons that are also excited by increases in plasma leptin 19 or by α-MSH. 24 Therefore, to test the involvement of PVN α-MSH, glutamate, and NPY inputs, we performed a series of nanoinjection experiments to block PVN MC3/4R, glutamatergic ionotropic receptors, and NPY Y1 receptors after leptin or artificial cerebrospinal fluid (aCSF) administration.
Methods
An expanded Methods section is available in the online-only Data Supplement.
Experimental Protocols
All procedures involving rats were approved by the Oregon Health & Science University Animal Care and Use Committee. Briefly, male Sprague-Dawley rats were anesthetized with isoflurane and prepared for ICV infusions, PVN or ArcN nanoinjections, and for measurements of mean arterial pressure (MAP), heart rate (HR), LSNA, and baroreflex control of LSNA and HR, as previously described. 4, 24 Then, a loading dose of α-chloralose (50 mg/kg) was administered intravenously over 30 minutes, while isoflurane was slowly withdrawn, and this was followed by a continuous infusion (25 mg/kg per hour) for the duration of the experiment.
continuously recorded for 2 hours, at which time either NPY1x or aCSF was injected bilaterally into the PVN. Measurements continued for a final 30 minutes.
Protocol 3: Is Reduced Tonic PVN NPY Inhibition Required for α-MSH Excitation of PVN Presympathetic Neurons?
Because presympathetic neurons that are inhibited by NPY are also excited by α-MSH, 24 we also determined whether the increase in LSNA in response to PVN nanoinjection of the MC3/4R agonist MTII is greater after PVN NPY1 receptor blockade. After baseline measurements of LSNA, MAP, and HR were made, either aCSF or NPY1x was injected into the PVN. After 30 minutes, either aCSF or α-MSH agonist MTII was injected into the PVN, and measurements were continued for an additional 30 minutes.
Statistical Analysis
All data are presented as means±SEM. Between-group differences were evaluated using 1-or 2-way ANOVA for repeated measures and the post hoc Newman-Keuls test. P values <0.05 were considered statistically significant.
Results

PVN Muscimol Completely Reverses the Effects of ICV Leptin
ICV leptin increased LSNA, MAP, and HR after 1 hour (Figure 1 ). Consistent with its slowly developing effects, 4, 10 these variables continued to rise (P<0.05, #) in rats receiving PVN aCSF injections after 30 minutes ( Figure 1A ), as shown previously in rats not receiving PVN injections. 4 PVN muscimol had no effects in ICV aCSF-treated animals ( Figure 1B ; Figures S1 and S2 in the online-only Data Supplement).
However, in rats receiving ICV leptin ( Figure 1C and 1D ), muscimol decreased (P<0.05, #) LSNA, MAP, and HR to values not different from baseline control values or from values in rats receiving ICV aCSF and PVN muscimol ( Figure 1B) .
As previously shown, 4 1 hour ICV leptin enhanced baroreflex control of LSNA by increasing (P<0.05) baroreflex gain, the baroreflex maximum, and the range (eg, from 102%±11% to 212%±21% in the Leptin-aCSF group; P<0.05; Figure S1 ). Forty minutes later, 10 minutes after PVN nanoinjection of aCSF, baroreflex gain, maximum, and range (to 278%±23%) were further increased ( Figure S1 ; P<0.05, #), and the baroreflex minimum was elevated (Figure S1 ; P<0.05). In contrast, after PVN muscimol, baroreflex gain, the maximum and minimum, and the range (from 122%±14% to 192%±21% [leptin], then to 124%±15% [muscimol], P<0.05) were decreased (P<0.05) back to baseline ( Figure S1 ). Also as shown previously, 4 leptin altered baroreflex control of HR by increasing HR at any given MAP without altering baroreflex gain; that is, the maximum and minimum and the BP50 were elevated 100 minutes after leptin injection (P<0.05). Again, PVN muscimol completely reversed these effects ( Figure S2 ). In contrast, nanoninjections of muscimol outside the PVN did not alter the effects of leptin ( Figures S3 and S13 ).
Blockade of PVN MC3/4R or Ionotropic Glutamatergic Receptors Each Partially Reverses the Effects of ICV Leptin
In rats receiving ICV aCSF, nanoinjections of SHU9119 or KYN had no effects (Figures 2 and 3 ; Figures S4-S7 ). On the contrary, after ICV leptin and then PVN SHU9119, basal LSNA, HR, and MAP failed to increase further, compared with the levels at 60 minutes, and were reduced (P<0.05, ‡) compared with rats given ICV leptin and PVN aCSF ( Figure 1A) . However, LSNA, HR, and MAP remained elevated compared with baseline control values and with values of rats receiving ICV aCSF and SHU9119 (Figure 2) .
Similarly, although leptin enhanced baroreflex control of LSNA after 60 minutes (gain, maximum, minimum, and BP50; P<0.05; Figure S4 ), these variables did not increase further in animals receiving PVN SHU9119 30 minutes later. As a result, baroreflex gain and maximum were lower than in rats receiving leptin and PVN aCSF. The ability of leptin to increase baroreflex control of HR was similarly reduced by PVN SHU9119 ( Figure S5 ). Nevertheless, although PVN SHU9119 partially reversed the effects of leptin to enhance baroreflex control of LSNA and HR, LSNA and HR baroreflex function remained elevated compared with pre-leptin baseline values ( Figures S4 and S5) .
The results were similar when PVN ionotropic glutamate receptors were blocked with KYN ( 
Combined Blockade of PVN MC3/4R and Ionotropic Glutamatergic Receptors Reverses the Effects of ICV Leptin Similarly to Either Alone
Because blockade of PVN MC3/4R and glutamate receptors each only partially reversed the effects of leptin, we next determined whether combined blockade normalizes baseline values and baroreflex function after ICV leptin. However, administration of SHU9119 followed 5 minutes later by KYN resulted in a similar reversal of the effects of leptin as either alone ( Figures S8 or S9 ). More specifically, in rats 105 minutes after ICV leptin, although PVN SHU+KYN decreased LSNA, HR, and MAP relative to rats receiving ICV leptin and PVN aCSF (Figure 1A) , these values remained elevated compared with the baseline control values, as well as values obtained in control animals receiving ICV aCSF and either SHU9119 or KYN in the PVN. Moreover, PVN SHU+KYN did not reduce LSNA, HR, and MAP in ICV leptin-infused rats more than either SHU9119 or KYN alone or compared with levels recorded after 60 minutes of leptin.
ICV and ArcN Leptin Attenuate the Sympathoexcitatory Effects of Blockade of PVN NPY Y1 Receptors
Ninety minutes after initiating the ICV infusion of aCSF, as previously reported, 24 PVN NPY1x increased LSNA, MAP, and HR ( Figure 4C and 4D) and baroreflex control of LSNA and HR (Figures S10 and S11). In contrast, after ICV leptin, 
PVN MTII Increases LSNA, MAP, and HR Only After PVN NPY1x
After PVN aCSF injections, bilateral PVN MTII failed to alter LSNA, MAP, or HR ( Figure 5 ). As previously mentioned, 24 PVN NPY1x induced sympathoexcitatory, pressor, and tachycardic effects, which were not altered by PVN aCSF (Figure 5 ). However, after PVN NPY1x, subsequent PVN MTII produced significant increases in LSNA, MAP, and HR ( Figure 5 ).
The histological locations of PVN and ArcN nanoinjections are illustrated in Figures S13 and S14.
Discussion
The purpose of the present study was to begin to delineate the neurocircuitry by which brain leptin increases LSNA and its baroreflex regulation. Our major new findings are the following: (1) PVN inhibition with muscimol completely reversed the effects of ICV leptin to increase LSNA, MAP, HR, and baroreflex control of LSNA and HR; (2) inhibition of PVN MC3/4R and ionotropic glutamate receptors each partially reversed the effects of leptin, and the effects of combined MC3/4R and glutamate receptor inhibition were similar to either alone; (3) the sympathoexcitatory, pressor, and tachycardic effects of blockade of PVN NPY Y1 receptors were eliminated by prior ICV or ArcN leptin administration; and (4) PVN nanoinjection of the α-MSH agonist MTII increased SNA only after blockade of PVN NPY Y1 receptors. Collectively, these data indicate that in male rats, ICV leptin increases LSNA in part via increased α-MSH and glutamatergic drive of PVN presympathetic neurons and by suppression of tonic NPY inhibition. Moreover, our data suggest that the removal of tonic NPY inhibition is required to unmask the increased α-MSH excitation of PVN presympathetic neurons.
Leptin has been shown to activate a network of sites to increase SNA 1 similarly to its effects on energy balance. We confirm that leptin administered ICV, as well as into the ArcN, increases SNA, HR, and MAP [3] [4] [5] 8, 10 and that ICV leptin enhances baroreflex control of LSNA and HR. 4 Because bilateral inhibition of the PVN with muscimol completely reversed the effects of leptin, we conclude that all sites (accessed and stimulated by ICV leptin) must converge either in or proximal to the PVN. The results also confirm the involvement of α-MSH, [17] [18] [19] and further show that MC3/4R in the PVN are specifically engaged in males as we recently demonstrated in females in protestrus.
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A major finding, however, was that unlike PVN muscimol, PVN SHU9119 only partially reversed the sympathoexcitatory effects of leptin. Because the present dose of PVN SHU9119 is similar to those used to significantly alter various aspects of energy balance 29, 30 and is sufficient to completely reverse comparable increases in SNA evoked by IV insulin 31 (which acts solely in the ArcN, 32,33 unlike leptin), additional excitatory mechanisms must be involved. Indeed, we found that KYN also reduced the stimulatory effects of leptin on LSNA and baroreflex function, implicating a glutamatergic input to the PVN in the leptin responses. Nevertheless, like SHU9119, although our dose of KYN largely reversed the sympathoexcitatory effects of IV insulin, 34 it only partially reduced the effects of leptin. Moreover, the combined effects of SHU9119 and KYN did not produce a greater effect than either alone. One interpretation of these results is that the sympathoexcitatory actions of PVN glutamate and α-MSH converge such that one mechanism occludes the other. However, previous studies demonstrated that MC3/4R agonists like MTII act postsynaptically to excite PVN neurons that project to the rostral ventrolateral medulla (RVLM) 24, 35, 36 and that MTII does not alter presynaptic release of glutamate. 35 Therefore, it is unlikely that SHU9119 blocked the effects of KYN by preventing MC3/4R enhancement of glutamate release. In addition, the sympathoexcitatory effects of PVN injection of N-methyl-d-aspartic acid are not altered by PVN SHU9119, 31 suggesting that the drug does not hinder postsynaptic effects of glutamate. Alternatively, glutamatergic and α-MSH inputs may have converged to elicit a maximal or ceiling level of sympathoexcitation via these combined mechanisms.
The finding that combined MC3/4R and glutamate receptor inhibition only partially reversed the effects of ICV leptin suggests that yet other excitatory mechanisms contribute. For example, leptin, by activating MC3/4R or glutamatergic metabotropic receptors, may trigger cellular signaling pathways that lead to events that are not rapidly reversed. In support, the sympathoexcitatory effects of leptin are well known to be slowly developing (eg, Figure 1 ) and to evoke cellular signaling.
37,38 Additionally, leptin may act directly in the PVN because previous studies demonstrated that injection of leptin into the PVN increases arterial pressure. 8, 11 Future experiments are required to test these possibilities.
Another major goal was to investigate whether decreased NPY inhibition is involved in leptin-induced sympathoexcitation. Because ICV leptin administration markedly inhibited the actions of PVN NPY1x to increase MAP and basal and baroreflex control of LSNA and HR, we conclude that, like local PVN NPY1x, leptin decreases tonic NPY inhibition of SNA, HR, and MAP, thereby contributing to its sympathoexcitatory effects. NPY inputs to PVN arise not only from the ArcN, but also from the brain stem.
39,40 Therefore, the finding that ArcN leptin similarly suppressed PVN NPY inhibition further indicates that the ArcN-to-PVN population of NPY neurons can contribute to leptin-induced sympathoexcitation and that leptin does not suppress NPY neuronal activity via binding in other hypothalamic sites. Finally, NPY and α-MSH inputs converge onto PVN presympathetic neurons because (1) these neurons express NPY Y1 and MC4 receptors, 24 ,36 (2) the increases in SNA and MAP after PVN NPY1x are prevented by prior inhibition of MC3/4R, 24 and (3) α-MSH excites and NPY inhibits single PVN-to-RVLM neurons. 24 Our present finding that PVN administration of a low dose of MTII 41 elicits sympathoexcitation only after prior blockade of NPY Y1R suggests that the simultaneous disinhibition of PVN presympathetic neurons through withdrawal of NPY tone is required for the excitatory effect of leptin-induced increases in α-MSH to prevail.
Interestingly, the neuronal circuitry by which insulin increases SNA is remarkably similar to that of leptin. Although insulin acts solely in the ArcN, 31-33 like leptin, it increases SNA via a neuronal pathway that includes the PVN 31,32 and the RVLM. 24, 42 Both α-MSH and glutamatergic inputs into the PVN are involved.
31,34 Because insulin and leptin are often increased together, such as after a meal or in insulin-resistant individuals, these parallel pathways may converge and amplify sympathoexcitatory effects. Moreover, because the effects of leptin 4 and insulin 31, 33, 43 to increase the activity of various sympathetic nerves are diverse, relative increases in leptin versus insulin may homeostatically and differentially engage increased sympathetic outflow to several organ beds.
Perspectives
Obesity increases SNA, in particular to the hindlimb and kidney, and elevations in leptin and hypothalamic melanocortin activity are widely viewed as essential. 44 Remarkably, however, the potential role of NPY in obesity-induced increases in SNA and MAP is completely unexplored. In rats and mice, diet-induced obesity decreases NPY expression in the PVN/ ArcN or NPY mRNA levels in the ArcN. [45] [46] [47] [48] [49] [50] Moreover, inbred obesity-prone rats exhibit decreases in NPY/Agoutirelated protein processes in PVN. 51 These data coupled with our current findings that a decrease in tonic NPY inhibition is required for leptin-induced increases in PVN MC3/4R drive of sympathetic outflow suggests that obesity also decreases tonic NPY inhibition of SNA, which unmasks the welldescribed increased α-MSH excitation. This information thus underscores the need for more research into the import of PVN NPY in obesity-induced sympathoexcitation. What Is New?
• Inhibition of the paraventricular nucleus (PVN) with muscimol completely reverses the effects of intracerebroventricular leptin to increase lumbar sympathetic nerve activity (LSNA), heart rate (HR), mean arterial pressure, and baroreflex control of LSNA and HR.
• Blockade of PVN MC3/4R and glutamate ionotropic receptors, alone or together, only partially reverses the effects of intracerebroventricular leptin to increase LSNA, HR, mean arterial pressure, and baroreflex control of LSNA and HR.
• Intracerebroventricular or arcuate injections of leptin prevent the normal increases in LSNA, mean arterial pressure, and HR after blockade of neuropeptide Y (NPY) Y1 receptors.
• PVN nanoinjections of the MC3/4R agonist, MTII, increase LSNA, mean arterial pressure, and HR only after blockade of PVN NPY Y1 receptors.
What Is Relevant?
• Obesity increases leptin, which has been shown to contribute to the sympathoexcitation and eventual hypertension. Recognition of the PVN as a site of convergence in the neurocircuitry may influence future experimental or treatment strategies. Figure S3 . Baseline LSNA, heart rate, and mean arterial pressure, and baroreflex control of LSNA and heart rate, were increased 1 hr after icv leptin injection, and these changes were not altered by bilateral nanoinjection of muscimol outside of the PVN 30 min later (i.e. not different from icv leptin plus PVN aCSF). See Figure S13 for location of injection sites (n=4). *: P<0.05 compared to baseline control values (CON); #: P<0.05 compared to 1 hr leptin within group; †: P<0.05 compared to icv aCSF at the same time. Figure S4 . Baroreflex control of LSNA was enhanced (increased BRG, maximum, minimum, BP50) following icv injection of leptin, and these changes were partially reversed by bilateral nanoinjection of SHU9119 into the PVN. *: P<0.05, compared to baseline control values (CON); #: P<0.05 compared to 1 hr leptin within group; †: P<0.05 compared to icv aCSF at the same time; ‡: P<0.05, icv leptin plus PVN SHU9119 compared to icv leptin plus PVN aCSF (as in Figure S1 ). Figure S5 . Baroreflex control of HR was enhanced (increased baroreflex maximum, minimum, BP50) following icv injection of leptin, and these changes were partially reversed by bilateral nanoinjection of SHU9119 into the PVN. *: P<0.05, compared to baseline control values (CON); #: P<0.05 compared to 1 hr leptin within group; †: P<0.05 compared to icv aCSF at the same time; ‡: P<0.05, icv leptin plus PVN SHU9119 compared to icv leptin plus PVN aCSF (as in Figure S2 ). Figure S6 . Baroreflex control of LSNA was enhanced (increased BRG, maximum, minimum, BP50) following icv injection of leptin, and these changes were partially reversed by bilateral nanoinjection of KYN into the PVN. *: P<0.05, compared to baseline control values (CON); #: P<0.05 compared to 1 hr leptin within group; †: P<0.05 compared to icv aCSF at the same time; ‡: P<0.05, icv leptin plus PVN KYN compared to icv leptin plus PVN aCSF (as in Figure S1 ). Figure S7 . Baroreflex control of HR was enhanced (increased baroreflex maximum, minimum, BP50) following icv injection of leptin, and these changes were partially reversed by bilateral nanoinjection of KYN into the PVN. *: P<0.05, compared to baseline control values (CON); *: P<0.05 compared to 1 hr leptin within group; †: P<0.05 compared to icv aCSF at the same time; ‡: P<0.05, icv leptin plus PVN SHU9119 compared to icv leptin plus PVN aCSF (as in Figure  S2 ). Figure  1A ). Figure S9 . Baroreflex control of LSNA (increased BRG, maximum, minimum, BP50) and HR (increased baroreflex maximum, minimum, BP50) were enhanced following icv injection of leptin, and these changes were partially reversed by bilateral nanoinjection of SHU+KYN into the PVN. *: P<0.05, compared to baseline control values (CON); #: P<0.05 compared to 1 hr leptin within group; ‡: P<0.05, icv leptin plus PVN SHU9119+KYN compared to icv leptin plus PVN aCSF (as in Figures S1 and S2 ). Figure S10 . Baroreflex control of LSNA was enhanced following icv injection of leptin (top; increased BRG, maximum, minimum, BP50) or bilateral PVN nanoinjection of NPY1x 90 min after icv aCSF injection (bottom; increased BRG and maximum). However, NPY1Rx failed to further increase baroreflex control of LSNA following icv leptin (middle). As a result, the baroreflex curve after icv leptin + PVN NPY1x (middle) was not different from that following icv leptin + PVN aCSF (top). *: P<0.05, compared to baseline control values (CON). #: P<0.05 compared to 1 hr leptin within group; †: P<0.05 compared to icv aCSF at the same time. Figure S11 . Baroreflex control of HR was enhanced following icv injection of leptin (top; increased maximum, minimum, BP50) or bilateral PVN nanoinjection of NPY1x 90 min after icv aCSF injection (bottom; increased maximum). However, NPY1Rx failed to further increase baroreflex control of HR following icv leptin (middle). As a result, the baroreflex curve after icv leptin + PVN NPY1x (middle) was not different from that following icv leptin + PVN aCSF (top). *: P<0.05, compared to baseline control values (CON). *: P<0.05 compared to 1 hr leptin within group; †: P<0.05 compared to icv aCSF at the same time. 
